A booster was 95.6% effective against symptomatic Covid in the study, which followed 10,000 people aged 16 and older, the companies said in a
Pfizer shares fell 0.7% as of 10:09 a.m. in New York. BioNTech’s American depositary receipts gained 3.3%.
“We believe boosters have a critical role to play in addressing ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.